Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

General Oncology

AstraZeneca Pauses COVID-19 Vaccine Trials

Diana Ernst, RPh

September 10, 2020

In a statement, the Company noted that the actions being taken are considered “routine” when an unexplained illness is reported in a clinical trial.

General Oncology

FDA Approves Blood-Based Test as Companion Diagnostic for Multiple Cancer Drugs

Diana Ernst, RPh

August 28, 2020

Using a blood sample, the test is able to analyze more than 300 cancer-associated genes for alterations.

General Oncology

Phase 3 Trial of COVID-19 Vaccine Candidate mRNA-1273 Begins

Diana Ernst, RPh

July 27, 2020

The trial, which is the first to be implemented under Operation Warp Speed, is expected to enroll around 30,000 adults and will be conducted at multiple clinical research sites across the US.

Lung Cancer

Zepzelca Approved for Metastatic Small Cell Lung Cancer

Diana Ernst, RPh

June 17, 2020

The FDA has approved Zepzelca™ (lurbinectedin; Jazz Pharmaceuticals) for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

General Oncology

Ready-to-Dilute Liquid Formulation of Akynzeo Injection Approved

Diana Ernst, RPh

June 4, 2020

The FDA has approved a new ready-to-dilute liquid formulation of Akynzeo® injection (fosnetupitant/palonosetron; Helsinn) for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, in combination with dexamethasone in adults.

Lung Cancer

Cyramza Plus Erlotinib Approved for First-Line Metastatic NSCLC With EGFR Mutations

Diana Ernst, RPh

June 3, 2020

The FDA has approved Cyramza (ramucirumab; Lilly) in combination with erlotinib, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.

Endocrine Cancer

FDA: Unacceptable NDMA Levels Identified in Certain Metformin ER Products

Diana Ernst, RPh

May 29, 2020

Specifically, unacceptable levels of this potentially carcinogenic impurity have been identified in products manufactured by 5 different firms.

Sarcoma

Pomalyst Gets Accelerated Approval for Kaposi Sarcoma

Diana Ernst, RPh

May 19, 2020

This indication was granted accelerated approval based on overall response rate (ORR) and continued approval may be contingent upon confirmatory trial results.

Lung Cancer

Opdivo Plus Yervoy Approved for First-Line Treatment of Metastatic NSCLC

Diana Ernst, RPh

May 18, 2020

The FDA has approved the combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

Gynecologic Cancer

Lynparza Plus Bevacizumab Approved for First-Line Maintenance in HRD-Positive Advanced Ovarian Cancer

Diana Ernst, RPh

May 11, 2020

The FDA has approved Lynparza® for use in combination with bevacizumab as first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer

Next post in Gynecologic Cancer